Erratum

This article refers to:

Genetic Profile of Patients with Epilepsy on First-Line Antiepileptic Drugs and Potential Directions for Personalized Treatment

In the article: Grover S, Gourie-Devi M, Baghel R et al.: Genetic profile of patients with epilepsy on first-line antiepileptic drugs and potential directions for personalized treatment. Pharmacogenomics 11(7), 927–941 (2010), the following figure was shown:

Figure 1. Frequency of the CYP2C9*1/*3 mutant genotype, representing the individuals with altered metabolism for CYP2C9 across 24 Indian subpopulations.

CYP2C9*1/*3 was the only mutant genotype detected in the Indian population. Mutant genotypes: CYP2C9*1/*2 or CYP2C9*1/*3 indicate intermediate metabolizer; CYP2C9*2/*2 or CYP2C9*2/*3 or CYP2C9*3/*3 indicate poor metabolizer.

AA: Austro–Asiatic; C: Central; DR: Dravidian; E: East; IE: Indo–European; IP: Isolated population; LP: Large population; N: North; NE: Northeast; S: South; SP: Special population; TB: Tibeto–Burman; W: West.

The figure should have appeared like this:

Figure 1. Frequency of the CYP2C9*1/*3 mutant genotype, representing the individuals with altered metabolism for CYP2C9 across 24 Indian subpopulations.

CYP2C9*1/*3 was the only mutant genotype detected in the Indian population. Mutant genotypes: CYP2C9*1/*2 or CYP2C9*1/*3 indicate intermediate metabolizer; CYP2C9*2/*2 or CYP2C9*2/*3 or CYP2C9*3/*3 indicate poor metabolizer.

AA: Austro–Asiatic; C: Central; DR: Dravidian; E: East; IE: Indo–European; IP: Isolated population; LP: Large population; N: North; NE: Northeast; S: South; SP: Special population; TB: Tibeto–Burman; W: West.

The authors and editors of Pharmacogenomics would like to sincerely apologize for any inconvenience caused.